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INTRODUCTION 
Stroke is the loss of cerebral function caused by the interruption of the blood supply to the brain that occasions variable symptoms depending on what area is affected. It ranks second as 
the cause of death worldwide. However, the clinical, social and economic burdens of stroke are not consequence of mortality; they are the result of the large majority of stroke patients 
who survive but are mentally or physically disabled. For this reason, there have been lots of investments trying to reach an appropriate treatment, but no attempt promises a great 
opportunity except for rtPA.  
 
 
 
AIMS 
 
 
STROKE  AND ISCHEMIC DAMAGE 
Apoptosis 
Ischemia 
Hypoxia 
Excitotoxicity 
Free radicals 
Inflammation 
CELL DEATH 
This occlusion will cause changes in 
microcirculation that will result in 
variable degrees of hipoperfusion across 
the ischemic zone. As a consequence, an 
adjacent area with lesser hipoperfusion is 
formed, which is called penumbra (brain 
area which preserves blood flux between 
functional and morphologic threshold). 
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Penumbra 
 
 
NEUROPROTECTION AND STROKE: Translational failure 
 
 
From bench to the bedside: improvements for a suitable translation  
• Re-evaluation of pathophysiology and Knowledge extension 
• Better animal models (older, with co-morbidities)  
• Increase sample size 
• Standardize outcome measures 
• Multi-stage approach 
• Optimize the therapeutic time window, dose and route of administration in 
humans 
 
NEUROPROTECTION AND GENE THERAPY 
 
 
Neuroprotection Gene Therapy 
Not preventive treatment Therapeutic treatment 
Structural and functional recovery not 
immediately 
Stable long-term expression 
Administration in specific moment Time lag 
1Endres M, Engelhardt B et al. 
Pathobiology of stroke induced 
damage, endogenous repair and 
regeneration. 
 
 
NEURAL PLASTICITY AND GENE THERAPY 
 
 
 
Neurogenesis 
Neural plasticity Gene Therapy 
Structural and functional recovery not 
immediately 
Stable long-term expression 
Broader time window Time lag 
Insufficient natural response Increases/ reinforces expression 
Unknowledge of details 
knowledge about its regulation and 
development over time  
On one hand, what is currently known about stroke 
nature only elicits therapeutic treatment because a 
preventive approach is not possible. On the other 
hand, structural and functional recovery is not 
achieved immediately after treatment; it is required 
a period of time to restore imbalance. Considering 
these aspects, gene therapy may be viewed as a 
good option to treat it, but molecular mechanisms 
induced by stroke have a quite well established time 
course which in turn means that the time to act is 
restricted and limited . 
 
 
Transient or permanent reduction of 
cerebral blood flow (CBF) which is 
associated with reduction of oxygen 
distribution (hypoxia), nutrients and 
elimination of metabolic products causes 
important impairments at tissue level 
known as ischemia.  This will induce a 
cascade of secondary effects which is the 
real cause of death because flux restoration 
does not prevent from cellular demise. 
Few available therapeutic options and numerous failed clinical trials seem to be a 
contradiction considering the intensive research efforts in this field.  
• Review the strategies tested - Analysis of failure in translational settings for preclinical 
to clinical. 
• Evaluate current feasibility of gene therapy. 
Neuroprotection refers to the intensively studied strategies, applied singly or in 
combination, which try to target the previous molecular events by antagonizing, 
interrupting or slowing them, especially in penumbra zone. Unfortunately, despite the 
amount of preclinical studies and clinical trials that have been performed, all attempts 
in ischemic stroke have failed. 
 
 
Penumbra is not just passively dying over time but it is also actively recovering; 
Homeostatic alterations induced by lack of oxygen and nutrients activate a neurorepair 
and neuroregeneration process (neurogenesis, angiogenesis and sinaptogenesis). 
Therefore, these mechanisms have been noticed as new strategies because they are 
much greater than previously thought.  
 
 
 
 
 
 
Few available therapeutic options and numerous failed clinical trials seem to be a 
contradiction considering the intensive research efforts in this field. So, it is obvious that 
this failure demands: 
• An examination of pathophysiology of ischemic brain injury 
• Changes in methodological process and progresses in gene therapy  
• A detailed knowledge about how the processes related to neurogenesis, angiogenesis 
and sinaptogenesis develop over time and how they are regulated 
To sum up, gene therapy is not an ideal option for the neuroprotection approach taking 
into account previous limitations. By contrast, it could be a suitable future tool by 
reinforcing neuronal growth if significant steps in knowledge of neuroregeneration were 
done. 
 
 
CONCLUSIONS 
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